Biocon to merge biologics unit; to acquire stake held by Serum, Mylan
The Hindu
Biocon plans to merge Biocon Biologics, acquiring remaining stakes for $5.5 billion, enhancing its global biosimilars and generics portfolio.
More Related News
Biocon plans to merge Biocon Biologics, acquiring remaining stakes for $5.5 billion, enhancing its global biosimilars and generics portfolio.